Infections represent a frequent complication of chemotherapy used for acute myeloid leukaemia (AML) and are associated with important toxicity frequently leading to treatment discontinuation. Acute promyelocytic leukaemia (APL) is a unique AML subset requiring tailored therapy including all-trans retinoic acid and anthracycline-based chemotherapy. We analysed in this study the incidence and type of infections complicating the clinical course of 89 consecutive APL patients receiving the AIDA protocol at a single institution. A total of 179 febrile episodes were registered during induction and consolidation, 52% of which were of unknown origin. Infections were clinically and microbiologically documented in 10.6 and 37.4% of cases, respectively. Coagulase-negative staphylococci represented the major cause of septicaemia (28%) and were more frequently isolated during induction, whereas viridans group streptococci, the second pathogen most frequently isolated from blood (27%), represented the principal pathogen detected during consolidation and were significantly associated with mucositis. Gram-negative bacteria accounted for 33.3% of all blood isolates. Fungal infections were only occasionally observed. Bloodstream infections in APL patients were compared with those documented in 271 consecutive patients affected by other subtypes of AML. The incidence of total septicaemia episodes, of staphylococcal bacteraemias and of fungaemias was significantly higher in patients with other AMLs. Empirical antibiotic therapy with ceftriaxone plus amikacin was effective in 73% of APL cases, most of the remaining cases being successfully managed by the addition of teicoplanin. One single death apparently related to infectious complication was recorded. Overall, infections led to antileukaemic treatment withdrawal in six patients, five of whom currently remain in haematologic remission for 13-106 months. These results indicate that a particular pattern of infections is observed in APL patients receiving ATRA plus anthracyclinebased chemotherapy and that these appear to be effectively counteracted by standard management. Leukemia (2003) 17, 925-930.
Introduction
Infections are a major complication in patients with acute myeloid leukaemia (AML) undergoing intensive chemotherapy and, in spite of recent improvements in antimicrobial and supportive therapies, these complications are still associated with severe morbidity and mortality, and represent a frequent cause of treatment withdrawal. Among AMLs, acute promyelocytic leukaemia (APL) is the subtype where the greatest progress in treatment has been made over the past decade. 1 In particular, the use of all-trans retinoic acid (ATRA) and its association with anthracycline-based chemotherapy have led to remission induction rates of more than 90% as reported by several large multicentre studies. [2] [3] [4] [5] [6] [7] [8] [9] Although primary resistance of APL to this combination is exceedingly rare, postremission chemotherapy is necessary in order to obtain prolonged molecular remission, a condition which in turn correlates with higher probability of long-term survival and cure. 10, 11 However, the intensity of consolidation to be administered in these patients is still a matter of controversy and recent investigations have shown that less-intensive schemes such as those used by the US MD Anderson 4, 12 or the Spanish PETHEMA groups 8 might be equally effective as compared to protocols including nonintercalating agents (cytarabine and others). Investigation on therapyrelated side effects and appropriate management of infections appears particularly relevant in a highly curable AML subset where severe life-threatening toxicity should be minimised.
This study reports our single centre experience on the incidence, characterisation and treatment of infections in patients with newly diagnosed APL uniformly treated with the AIDA (ATRA plus idarubicin) protocol. Furthermore, we analyse the influence of infective complications in completion of the assigned therapeutic programme and in the outcome of the underlying malignancy.
Patients and methods
During the period October 1993-March 2001, 89 consecutive patients with newly diagnosed PML/RARa-positive APL were eligible to receive intensive chemotherapy with the AIDA protocol at the Dipartimento di Biotecnologie Cellulari ed Ematologia of the University La Sapienza of Rome, Italy. There were 42 males and 47 females, the median age was 40 years (range, 1-77 years). Median WBC and platelet number at diagnosis were 2900/mm 3 (range 350-145 000) and 28 500/ mm 3 (range 7000-210 000), respectively. The treatment schedule of the protocol is described in detail elsewhere 7 , by brief i.v. infusion, day 1 + Ara-C 150 mg/m 2 , every 8 h subcutaneously, days 1,2,3,4,5 + 6-thioguanine 70 mg/m 2 , every 8 h p.o., days 1,2,3,4,5. Patients were treated in the ordinary wards for induction until achievement of haematological complete remission (CR) and normalisation of peripheral blood counts. Each of the three scheduled consolidation courses was administered at recovery from the previous cycle when polymorphonuclear (PMN) and platelet (PLT) counts were 41500/mm 3 and 4100 000 mm 3 , respectively. According to a protocol amendment, since January 1997, patients aged Z65 years received only the first consolidation course. At the end of consolidation, residual disease was assessed in all cases by RT-PCR of PML-RARa, as described. 13 Patients who tested PCR positive at the end of consolidation, underwent, if eligible, allogeneic bone marrow transplantation in first CR. The first two consolidation courses and the third course were administered on an in-patient and outpatient basis, respectively. Usually, patients treated as in-patients were discharged at the end of each cycle regardless of their absolute PMN and PLT count, provided they were in good clinical conditions, without fever and/or bleeding and not receiving i.v. therapy. The required condition for outpatient management in this postconsolidation phase was a limited distance between patient's residence and hospital location (o2 h, by car). Patients living too far from the hospital were allocated to a nearby residence specifically dedicated to host patients and their relatives. Only a few patients with difficult peripheral vein access had an indwelling central venous catheter. Adult patients received antibacterial prophylaxis with oral ciprofloxacin (500 mg twice a day) during the neutropenic phase after induction and consolidation courses until increase of PMN to Z1000/mm 3 . Oral amphotericin B was administered as antifungal prophylaxis. Outpatients were routinely evaluated twice weekly on an ambulatory basis. In the event of any kind of emergency occurring at home, a haematological emergency unit (HEU) dedicated to outpatients with haematological diseases was available at our institution. 14, 15 In the event of fever or other signs of infection during neutropenia, blood cultures as well as cultures from any presumed site of infection were obtained, and a chest radiograph was performed . True septicaemia was defined as the isolation of a bacterial or fungal pathogen from a single blood culture for all microorganisms, but coagulase-negative staphylococci for which at least two positive blood cultures in the same day were required. After a clinical, laboratory and microbiologic check, patients were empirically treated with an antibiotic combination, usually daily i.v. ceftriaxone (2 g) plus amikacin (20 mg/kg). Neutropenic outpatients were instructed to check themselves for vital parameters including oral temperature and, in case of fever (body temperature 4381C), they were referred to our HEU and were hospitalised. Upon arrival at the HEU, a complete clinical and laboratory check was performed and empirical antibiotic therapy was started as above. Empirical therapy was adjusted on the basis of therapeutic response and the results of culture and sensitivity tests. Antibiotic treatment was continued for four consecutive days without fever or until disappearance of microbiological and/or clinical evidence of infection.
Results
Of 89 patients eligible for intensive chemotherapy, 86 completed induction and three died of haemorrhage during the first days of treatment. Three additional patients completed induction therapy, but did not receive consolidation due to refusal of further treatment (two cases) and severe cardiac complication (one case). After the achievement of CR, a total of 83 patients received at least one cycle of consolidation, while 73 and 63 patients received two and three courses, respectively. Of the 20 patients who received less consolidation, 14 were withdrawn due to therapy-related toxicity and six were patients aged Z65 who received only one cycle according to the amended protocol.
The incidence and type of infections in the various treatment phases are summarised in Tables 1 and 2 . Of the 179 febrile episodes, 93 (52%) were of unknown origin. An infection was clinically documented in 19 cases (10.6%) and microbiologically documented in 67 cases (37.4%). A significantly lower incidence of febrile episodes occurred after consolidation III compared to induction (Po0.0001), consolidation I (P ¼ 0.007) and consolidation II (Po0.0001). Gram-positive and Gramnegative bacteria accounted for 63 and 36% of all 67 blood isolates, respectively. Bloodstream Candida spp. infection was documented in only one case. Streptococcus viridans represented the organism most frequently isolated from blood (18/67, 27%), followed by coagulase-negative Staphylococcus (17/67, 25%) and Escherichia coli (11/67, 16%). All of 24 Gramnegative isolates were susceptible 'in vitro' to amikacin and 19 (79%) were susceptible to ceftriaxone. Streptococci were susceptible to ceftriaxone and amikacin in 100 and 78% of the cases, respectively, whereas staphylococci were susceptible to the two single drugs in 14 and 32% of the cases, respectively (36% of staphylococci were susceptible to oxacillin and 100% to vancomycin and teicoplanin). Febrile episodes and coagulase-negative staphylococcal infections were significantly more frequent after induction therapy as compared to consolidation therapy. The incidence of specific infections was evaluated in 71 courses in which the patients developed oral mucositic (WHO grades 2-4) as compared to 237 courses in which the patients developed no or mild mucositis. Mucositis was Bloodstream infections in APL patients were compared with those documented in 271 patients affected by other subtypes of AML who received standard intensive chemotherapy at our centre in the same period. In the latter group, treatment consisted of an anthracycline or anthacycline-like drug given for 3 days in combination with cytosine arabinoside given for 7-10 days and etoposide given for 3-5 days. 16, 17 In order to have a group better comparable with the APL series, we included in this analysis those AML patients who received one course of induction therapy. The median age of patients with other AMLs was 45 years. The FAB subtypes were M0 in 13(5%) cases, M1 in 48 (18%) cases, M2 in 86 (32%) cases, M4 in 61 (22%) cases, M5 in 55 (20%) cases and M6 in eight (3%) cases. The mean duration of neutropenia (PMNo500/mm 3 ) was 27 days for induction and 21 days for consolidation treatments. Complete remission after the first induction treatment was achieved in 187 (69%) patients, and, out of them, 165 received a consolidation course. The incidence of total septicaemia episodes was significantly higher in patients with other AMLs both in induction and consolidation phases of treatment (Table  3 ). In particular, fungaemias have been documented only in patients with AMLs other than APL during induction, and the incidence of coagulase-negative staphylococcal bacteraemia was significantly higher in other AMLs compared to APL during consolidation.
In the 179 episodes of febrile neutropenia that occurred in APL patients, the antibiotic associations ceftriaxone plus amikacin and piperacillin plus amikacin were empirically administered in 171 and eight cases, respectively. A total of 131 febrile episodes (73%) responded to the initial therapy while in 48 cases (27%) the fever disappeared after treatment modification. Teicoplanin was added in 42 cases, beta-lactam was substituted with meropenem or ceftazidime in six cases and an antifungal drug (amphotericin B or fluconazole) was added to the antibacterial treatment in six cases.
Of the 14 patients who did not complete the assigned consolidation therapy, six patients were withdrawn because of infectious complications (deep invasive mycoses and severe bacterial infections, three cases each); these occurred after the first consolidation course (one patient) or after the second course (five patients). Despite not completing the assigned consolidation treatment, five patients remained in continuous complete remission (CCR) after a median time of 67 months (range 13-106 months). One patient died in CR of intestinal haemorrhage after prolonged pancytopenia.
Overall, 14 deaths were registered after the achievement of CR. Of these, seven were because of leukaemia relapse and seven occurred in CR. In the latter group, a 65-year-old patient, who completed the assigned amended protocol including one single consolidation course, died of multiorgan failure with fever and staphylococcal plus enterococcal septicaemia while in maintenance therapy with ATRA and after 13 months in CR. The remaining six deaths in CR were owing to noninfective causes (haemorrhage, four cases; secondary solid tumour, one case; cardiac failure, one case).
Discussion
During the past decade, the advent of ATRA and its inclusion in combinatorial protocols with chemotherapy for front-line therapy of APL have dramatically improved the outlook of this disease. [2] [3] [4] [5] [6] [7] [8] [9] While ameliorating the disease associated coagulopathy as well as long-term outcome, the use of ATRA has been associated in a fraction of cases with a newly described severe complication referred to as ATRA-syndrome 18 whose incidence and morbidity seems reduced when chemotherapy is administered concomitantly. 19 Since they include intensive chemotherapy, these modern regimens are also associated with severe toxicity derived from prolonged cytopenia which in turn may result in life-threatening haemorrhages and/or infections frequently leading to treatment withdrawal in a considerable proportion of cases. Both prevalence and severity of such (24) 6 (6.7%) 18 (8.2%) NS E. coli (11) 1 (1.1%) 10 (4.6%) NS Enterobacter cloacae (3) 2 (2.2%) 1 (0.5%) NS Pseudomonas spp. (5) 2 (2.2%) 3 (1.4%) NS Other Gram-negative (5) 1 (1.1%) 4 (1.8%) NS Candida tropicalis (1) 0 1 (0.5%) NS
Infections in acute promyelocytic leukaemia C Girmenia et al complications are higher in the elderly population, where up to 19% of deaths in CR have been reported. 5 In the light of these observations, and considering the high curability of the disease, attempts to reduce the intensity of treatment appear extremely relevant.
Although there is general agreement on the inclusion of ATRA for induction, the type and intensity of chemotherapy to be used in both induction and consolidation phases is still a matter of investigation, such that there is considerable heterogeneity in both chemotherapy induction and consolidation approaches adopted by different groups.
In the present study, we investigated retrospectively infectious complications that occurred in patients treated with the AIDA protocol at a single institution. Besides analysing the incidence and type of infections developing in a specific leukaemic and therapeutic context, this study offered an opportunity to evaluate the prognostic impact of infections and antileukaemic treatment discontinuations on disease outcome.
Febrile neutropenia was more frequent during induction as compared to consolidation phases, and in patients with oral mucositis. During consolidation, a lower incidence of febrile episodes occurred after course III as compared to courses I and II. Bacteria represented the major cause of infection. Microbiologically or clinically documented fungal infections were diagnosed in less than 5% of patients. With regard to viral infections, only few cases of Herpes simplex and Herpes zoster infections were observed (data not shown).
Staphylococci represented the major cause of septicaemia and were more frequently isolated during induction as compared to consolidation phases. This finding is not surprising since it was observed in in-patients who did not have an indwelling CVC but rather had a plastic peripheral vein access (Venflon) inserted prior to and during chemotherapy and maintained for the whole period of hospitalisation. Only few cases of staphylococcal bacteraemia were documented in the outpatient setting during consolidation therapy. Viridans group streptococci were the second pathogen most frequently isolated from blood and represented the major cause of septicaemia during consolidation. Viridans streptococci, part of the normal human commensal flora, have recently emerged as important pathogens in cancer patients. 20, 21 The increased frequency of these infections has been attributed to several factors, including high-dose chemotherapy (particularly with cytosine arabinoside), oropharyngeal mucositis and prophylactic therapy with fluoroquinolones. Streptococcal bacteraemia is usually considered to derive from patient's own gastrointestinal flora, and oral mucosa has been demonstrated to be the portal of entry. 21 Nevertheless, some investigators have suggested that the gastrointestinal mucosa or central venous lines may represent potential sources for these infections in cancer patients. [22] [23] [24] [25] In the present series, oral mucositis appeared to be the major portal of entry of streptococcal bacteraemia as the patients did not have a central venous catheter, and signs of bowel wall damage because of gastrointestinal toxicity were only occasionally observed. Overall, 78% of infections documented during induction/consolidation phases occurred in patients with oral mucositis, and the risk of developing a viridans streptococcal bacteraemia was considerably higher for APL patients who developed stomatitis as compared to those who did not.
The analysis of septicaemias in patients with APL and in those with other AMLs showed a significantly higher rate of bloodstream infections in the latter group. In particular, fungal bloodstream infections were documented in only 1.1% of APL patients as compared to 6.3% of patients with other AMLs during induction or consolidation treatment. The incidence of both Gram-positive and Gram-negative bacterial septicaemias was significantly higher in AMLs other than APL during consolidation therapy and the difference was particularly high when coagulase-negative staphylococci were considered. Pneumonia represented the most common clinically documented infection in APL patients and its incidence did not significantly differ in the various phases of induction/consolidation treatment. Neutropenic enterocolitis is a severe complication associated to intensive chemotherapy of acute leukaemia. In a series of 250 adult patients with AML other than APL treated with intensive chemotherapy in the period 1992-2000 at our institution, neutropenic enterocolitis occurred in about 30% of cases (unpublished data). In accordance with the data of large multicentre trials, 7, 8 our study shows that gastrointestinal infections represent an unusual complication of the AIDA regimen and only two (2.2%) patients met the criteria for a diagnosis of enterocolitis during induction therapy. In both cases, the clinical signs were mild and either patients recovered within a few days with antimicrobial and supportive therapy. Furthermore, the low incidence of enterococcal septicaemia (only one case was registered during induction) is an indirect confirmation of the limited gastrointestinal toxicity of this protocol.
One of the aims of the present study was to evaluate the influence of infectious complications in the completion of therapeutic programme and, consequently, in the outcome of the underlying malignancy. Of the 14 patients who did not complete the assigned consolidation therapy, six were withdrawn owing to infectious complications. This observation confirms that of the GIMEMA multicentre study 7 in which 16 (9.8%) of the 162 valuable patients did not complete the three consolidation courses because of therapy-related toxicity, with treatment withdrawal because of infection occurring in nine patients (5.6% of the total population). We compared our data on infectious risk in APL patients with those reported in other APL studies in which the intensity of antileukaemic treatment was different. [2] [3] [4] [5] [6] 8, 9 The results of the modified AIDA regimen adopted by the PETHEMA group, 8 who adopted the same induction but a less-intensive consolidation therapy compared to the GIMEMA study, showed a significantly lower toxicity rate during consolidation, and all patients were able to complete the three courses of chemotherapy as initially scheduled. In particular, the incidence of febrile episodes was 14, 63 and 8% in the three consolidation courses, respectively. The low rate of infective complications in the Spanish experience is probably related to the less-intensive schedule that was associated to a low haematological toxicity with neutropenia occurring in 28, 94 and 17% of the patients in the three courses, respectively. In the study of the German AML Cooperative Group, 6 an intensified double induction therapy was adopted that included high-dose cytarabine in combination with ATRA followed by an intensive consolidation course. Infections of WHO grades Z3 occurred in 36 and 12% of patients after induction and consolidation, respectively. However, only two patients died because of an infectious complication after the second induction cycle and after consolidation, respectively. The impact of induction intensity in the incidence of infections clearly emerges in the study by Tallman et al, 9 in which patients were randomly assigned to receive ATRA alone or high-dose cytarabine plus daunorubicin. Life-threatening and lethal infections occurred in 8 and 6% of patients receiving chemotherapy, respectively, and in 3 and 1% of patients receiving ATRA, respectively.
Taken together, all the above-mentioned studies confirm the important and well-established role of treatment intensity in the incidence of infectious complications. In our study, however, only one patient died in CR because of an infectious complication, and infection-related treatment withdrawal of patients did not affect negatively the outcome of the underlying malignancy.
In conclusion, infective complications developing in APL patients receiving the AIDA protocol show consistent microbiological and clinical patterns that significantly differ from those observed in the other AML subsets, and that appear to be effectively counteracted by standard management. The favourable outcome of the small number of analysable patients who received less treatment due to infectious complications suggests that a reduction of treatment intensity that has been proposed for low-risk patients with this disease 26 deserves to be further explored.
